Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals reported robust financial results for Q4 FY25, with revenues growing 19.5% year-over-year to INR 2,116 crores. Domestic business saw a significant 25% growth, while international business grew 16%. For the full fiscal year 2025, the company achieved a top-line growth of 18.5% to INR 7,896 crores, with PAT increasing 34.1% to INR 707 crores. EBITDA margins for Q4 stood at 18.4%, supported by operating leverage despite lower gross margins of 57.8% due to product mix.

FY25 was a transformational year for Emcure's domestic operations. The company successfully integrated the Sanofi cardio business into its portfolio, which contributed INR 440-450 crores in FY25 despite product shortages. Emcure sharpened its focus on the derma segment with the launch of its subsidiary, Emcutix, introducing differentiated products like PRX-PLUS and Flawzilo. The women's health portfolio was expanded, and the company entered the OTC segment with Arth and Galact brands, aiming for low double-digit growth in the domestic market for FY26.

International markets demonstrated strong momentum, growing 16% in Q4 FY25 and 20% for the full year. Emerging Markets grew 27% in FY25, with expectations of closer to 20% growth in FY26. Canada outperformed with 35% growth in FY25, aided by the integration of the Mantra subsidiary. In the European Union, Emcure received approval for Amphotericin B Liposomal, marking it as the first generic to receive such approval in the EU, and also acquired Manx Healthcare's portfolio to expand its UK offerings.

Emcure provided an optimistic outlook for FY26, guiding for a top-line growth of 13% to 14% and an improvement of approximately 150 basis points in margins. This improvement is expected to be driven by operating leverage, increased productivity from new field force, synergies from restructuring efforts, and a more favorable product mix from new launches. Management also expressed a long-term aspiration for 300-400 bps margin improvement over the next 3-4 years, emphasizing execution across all segments.

The company made significant strides in strengthening its balance sheet, reducing net debt to INR 488 crores in FY25 from INR 1,558 crores in FY24. Management aims to achieve a debt-free status by the end of FY26. Planned capital expenditure for FY26 is estimated to be around INR 350 crores. For shareholders, the board recommended a dividend of INR 3 per share for FY25.

Emcure is actively developing a differentiated product pipeline. Its Gennova subsidiary has Bevacizumab for wAMD in Phase III, with a launch expected in FY26, marking its entry into the ophthalmic segment. The company has also filed for approval of R-Asparaginase in oncology, which will be the first time this recombinant product is available in India. Emcure is also on track to be in the first wave of launches post-expiry for semaglutide and is exploring complex injectables, biosimilars, new drug delivery routes, and ADC (Antibody-Drug Conjugates) through its Scientific Advisory Committee.

The newly launched derma subsidiary, Emcutix, which began operations in January, is focusing on a broad range of areas including cosmetology, geriatric care, and anti-pollution products. It currently has 8 brands with 6 more in the pipeline for the next 12 months. In women's health, Emcure launched new products for menopause and PCOS segments and plans further launches in FY26, aiming to address unmet needs and capitalize on the significant market potential for these rapidly growing areas.